Tobias Nordström1, Andrew Vickers2, Melissa Assel2, Hans Lilja3, Henrik Grönberg4, Martin Eklund5. 1. Department of Clinical Sciences, Danderyd's Hospital, Karolinska Institutet, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: tobias.nordstrom@ki.se. 2. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 3. Departments of Laboratory Medicine, Surgery (Urology), and Medicine (Genitourinary Oncology), Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Department of Laboratory Medicine, Lund University, Skåne University Hospital, Malmö, Sweden. 4. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 5. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Surgery, University of California at San Francisco, San Francisco, CA, USA.
Abstract
BACKGROUND: The four-kallikrein panel and the Prostate Health Index (PHI) have been shown to improve prediction of prostate cancer (PCa) compared with prostate-specific antigen (PSA). No comparison of the four-kallikrein panel and PHI has been presented. OBJECTIVE: To compare the four-kallikrein panel and PHI for predicting PCa in an independent cohort. DESIGN, SETTING, AND PARTICIPANTS: Participants were from a population-based cohort of PSA-tested men in Stockholm County. We included 531 men with PSA levels between 3 and 15 ng/ml undergoing first-time prostate biopsy during 2010-2012. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Models were fitted to case status. We computed calibration curves, the area under the receiver-operating characteristics curve (AUC), decision curves, and percentage of saved biopsies. RESULTS AND LIMITATIONS: The four-kallikrein panel showed AUCs of 69.0 when predicting any-grade PCa and 71.8 when predicting high-grade cancer (Gleason score ≥7). Similar values were found for PHI: 70.4 and 71.1, respectively. Both models had higher AUCs than a base model with PSA value and age (p<0.0001 for both); differences between models were not significant. Sensitivity analyses including men with any PSA level or a previous biopsy did not materially affect our findings. Using 10% predicted risk of high-grade PCa by the four-kallikrein panel or PHI of 39 as cut-off for biopsy saved 29% of performed biopsies at a cost of delayed diagnosis for 10% of the men with high-grade cancers. Both models showed limited net benefit in decision analysis. The main study limitation was lack of digital rectal examination data and biopsy decision being based on PSA information. CONCLUSIONS: The four-kallikrein panel and PHI similarly improved discrimination when predicting PCa and high-grade PCa. Both are simple blood tests that can reduce the number of unnecessary biopsies compared with screening with total PSA, representing an important new option to reduce harm. PATIENT SUMMARY: Prostate-specific antigen screening is controversial due to limitations of the test. We found that two blood tests, the Prostate Health Index and the four-kallikrein panel, performed similarly and could both aid in decision making among Swedish men undergoing a prostate biopsy.
BACKGROUND: The four-kallikrein panel and the Prostate Health Index (PHI) have been shown to improve prediction of prostate cancer (PCa) compared with prostate-specific antigen (PSA). No comparison of the four-kallikrein panel and PHI has been presented. OBJECTIVE: To compare the four-kallikrein panel and PHI for predicting PCa in an independent cohort. DESIGN, SETTING, AND PARTICIPANTS: Participants were from a population-based cohort of PSA-tested men in Stockholm County. We included 531 men with PSA levels between 3 and 15 ng/ml undergoing first-time prostate biopsy during 2010-2012. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Models were fitted to case status. We computed calibration curves, the area under the receiver-operating characteristics curve (AUC), decision curves, and percentage of saved biopsies. RESULTS AND LIMITATIONS: The four-kallikrein panel showed AUCs of 69.0 when predicting any-grade PCa and 71.8 when predicting high-grade cancer (Gleason score ≥7). Similar values were found for PHI: 70.4 and 71.1, respectively. Both models had higher AUCs than a base model with PSA value and age (p<0.0001 for both); differences between models were not significant. Sensitivity analyses including men with any PSA level or a previous biopsy did not materially affect our findings. Using 10% predicted risk of high-grade PCa by the four-kallikrein panel or PHI of 39 as cut-off for biopsy saved 29% of performed biopsies at a cost of delayed diagnosis for 10% of the men with high-grade cancers. Both models showed limited net benefit in decision analysis. The main study limitation was lack of digital rectal examination data and biopsy decision being based on PSA information. CONCLUSIONS: The four-kallikrein panel and PHI similarly improved discrimination when predicting PCa and high-grade PCa. Both are simple blood tests that can reduce the number of unnecessary biopsies compared with screening with total PSA, representing an important new option to reduce harm. PATIENT SUMMARY:Prostate-specific antigen screening is controversial due to limitations of the test. We found that two blood tests, the Prostate Health Index and the four-kallikrein panel, performed similarly and could both aid in decision making among Swedish men undergoing a prostate biopsy.
Authors: Peter R Carroll; J Kellogg Parsons; Gerald Andriole; Robert R Bahnson; Daniel A Barocas; Erik P Castle; William J Catalona; Douglas M Dahl; John W Davis; Jonathan I Epstein; Ruth B Etzioni; Thomas Farrington; George P Hemstreet; Mark H Kawachi; Paul H Lange; Kevin R Loughlin; William Lowrance; Paul Maroni; James Mohler; Todd M Morgan; Robert B Nadler; Michael Poch; Chuck Scales; Terrence M Shaneyfelt; Marc C Smaldone; Geoffrey Sonn; Preston Sprenke; Andrew J Vickers; Robert Wake; Dorothy A Shead; Deborah Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2015-12 Impact factor: 11.908
Authors: Massimo Lazzeri; Alexander Haese; Alexandre de la Taille; Joan Palou Redorta; Thomas McNicholas; Giovanni Lughezzani; Vincenzo Scattoni; Vittorio Bini; Massimo Freschi; Amy Sussman; Bijan Ghaleh; Philippe Le Corvoisier; Josep Alberola Bou; Salvador Esquena Fernández; Markus Graefen; Giorgio Guazzoni Journal: Eur Urol Date: 2013-01-24 Impact factor: 20.096
Authors: Andrew J Vickers; Angel M Cronin; Gunnar Aus; Carl-Gustav Pihl; Charlotte Becker; Kim Pettersson; Peter T Scardino; Jonas Hugosson; Hans Lilja Journal: BMC Med Date: 2008-07-08 Impact factor: 8.775
Authors: Andrew J Vickers; David Ulmert; Daniel D Sjoberg; Caroline J Bennette; Thomas Björk; Axel Gerdtsson; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; Hans Lilja Journal: BMJ Date: 2013-04-15
Authors: Scott E Eggener; Ketan Badani; Daniel A Barocas; Glen W Barrisford; Jed-Sian Cheng; Arnold I Chin; Anthony Corcoran; Jonathan I Epstein; Arvin K George; Gopal N Gupta; Matthew H Hayn; Eric C Kauffman; Brian Lane; Michael A Liss; Moben Mirza; Todd M Morgan; Kelvin Moses; Kenneth G Nepple; Mark A Preston; Soroush Rais-Bahrami; Matthew J Resnick; M Minhaj Siddiqui; Jonathan Silberstein; Eric A Singer; Geoffrey A Sonn; Preston Sprenkle; Kelly L Stratton; Jennifer Taylor; Jeffrey Tomaszewski; Matt Tollefson; Andrew Vickers; Wesley M White; William T Lowrance Journal: J Urol Date: 2015-04-04 Impact factor: 7.450
Authors: Stacy Loeb; Sanghyuk S Shin; Dennis L Broyles; John T Wei; Martin Sanda; George Klee; Alan W Partin; Lori Sokoll; Daniel W Chan; Chris H Bangma; Ron H N van Schaik; Kevin M Slawin; Leonard S Marks; William J Catalona Journal: BJU Int Date: 2016-11-22 Impact factor: 5.588
Authors: Andrew Vickers; Emily A Vertosick; Daniel D Sjoberg; Monique J Roobol; Freddie Hamdy; David Neal; Anders Bjartell; Jonas Hugosson; Jenny L Donovan; Arnauld Villers; Stephen Zappala; Hans Lilja Journal: J Urol Date: 2016-09-28 Impact factor: 7.450